Purchase Order 75N91019P00387

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $12,098.14 on May 5, 2021, for custom gene synthesis, custom peptide synthesis, direct cloning, plasmid preparation, and crude peptide library services. The order carries no small business set-aside. Work is performed in Piscataway, New Jersey, with an ultimate completion date of June 15, 2021.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $11,578.26 on June 11, 2019, covering custom gene synthesis, custom peptide synthesis, direct cloning, plasmid preparation, and crude peptide library services. No set-aside was used. Work is performed in Piscataway, New Jersey. The order was firm fixed price with an ultimate completion date of July 11, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $11,484.18 on August 12, 2019, for sequencing services. Work is performed in Piscataway, New Jersey. The order carries a firm fixed price and is scheduled for completion by September 11, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. valued at $3,964.20 on September 5, 2017, for peptide services. Work is performed in Piscataway, New Jersey. The order carries a firm fixed price structure and ultimate completion date of October 5, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $3,567.96 on August 11, 2017, for peptide services. Work is performed at the awardee's facility in Piscataway, New Jersey. The order is firm fixed price and carries a completion date of September 30, 2017.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $11,179.50 on November 18, 2019, for customized gene production, gene synthesis, and cloning services.</p> <p>Place of performance is Piscataway, New Jersey. The order carries a firm fixed price and ultimate completion date of December 6, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for sequencing services valued at $12,068.21, with an award date of September 12, 2019 and completion date of October 12, 2019. Work is performed in Piscataway, New Jersey. The order is firm fixed price with no small business set-aside.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. valued at $6,230.90 on April 2, 2018, with an ultimate completion date of May 3, 2018. No set-aside category was used. Place of performance is Piscataway, New Jersey. The order carries firm fixed price pricing for biotechnology and molecular biology services, consistent with Genscript's core offerings in gene synthesis, protein production, and antibody development for federal research institutions.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for peptide services on August 17, 2017, with a ceiling value of $8,353.96 and an ultimate completion date of September 30, 2017. Work is performed in Piscataway, New Jersey. The order is a firm fixed price purchase order with no set-aside.</p>

This is a $3,078,000.00 firm fixed-price contract awarded by the National Cancer Institute (NCI) to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract is for the provision of gene synthesis, peptide synthesis, and quality control analysis services to support the NCI Surgery Branch's clinical research efforts on mutation-reactive T-cells for the treatment of metastatic cancers. The contract has a 12-month base period with two 12-month option periods. There...